1.03 USD
↘ 0.29 (21.97%)AT CLOSE (11:59 AM EDT)
ADC Therapeutics SA
ADCTNYSE • USD
1.07
↗ 0.04 (3.40%)
POST MARKET (AS OF 08:14 PM EDT)
Post Market
AS OF 08:14 PM EDT
1.07
↗ 0.04 (3.40%)
Market: CLOSED
Open?$1.36
High?$1.38
Low?$1.02
Prev. Close?$1.32
Volume?7.6M
Avg. Volume?1.7M
VWAP?$1.17
Rel. Volume?4.54x
Bid / Ask
Bid?$1.06 × 800
Ask?$1.07 × 3.4K
Spread?$0.01
Midpoint?$1.07
Valuation & Ratios
Market Cap?131.0M
Shares Out?127.2M
Float?91.0M
Float %?73.5%
P/E Ratio?N/A
P/B Ratio?-0.61
EPS?-$1.08
Dividend?0.00%
Ex-Dividend?N/A
ADC Therapeutics SA (ADCT) is currently trading at $1.03. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (63.3%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest ADCT is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Employees
193
Market Cap
131.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-05-15
Address
BIOPOLE
EPALINGES, V8 1066
Phone: 41 21 653 02 00
EPALINGES, V8 1066
Phone: 41 21 653 02 00
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?17
Short Sent.?49
Piotroski F-Score?3/9Weak
Altman Z-Score?-8.07Distress
Confidence?58%Low
Short InterestElevated
Short % of Float?6.31%Elevated
Short Interest?5.7M
Days to Cover?4.0
Free Float91.0M
Avg Daily Volume1.5M
Settlement Date2026-05-15
Financial Health
Current Ratio?4.09Strong
Quick Ratio?4.02Strong
Cash Ratio?3.42Strong
Debt/Equity?-0.53Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-0.61CHEAP▾
S&P97
P/S?1.65CHEAP▾
Peers100
S&P76
P/FCF?N/A▾
EV/EBITDA?-0.2CHEAP▾
S&P97
EV/Sales?0.20CHEAP▾
Peers100
S&P97
Returns & Efficiency
ROE?63.3%STRONG▾
Peers50
S&P93
ROA?-47.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-114582000
Enterprise Value?$15.7M
Fundamentals ratios updated end of day